The case we present concerns a 77‐year‐old man
Case: Male, 77 years at report, ethnicity not reported
DiseaseAssertion: VWD2M
FamilyInfo: No known family history of bleeding; no pedigree provided.
ParentalGenotype: NA
CasePresentingHPOs: HP:0003645, HP:0003125, HP:0012147, HP:0030129
(Prolonged partial thromboplastin time, Reduced factor VIII activity, Reduced quantity of von Willebrand factor, Impaired ristocetin cofactor assay activity)
CaseHPOFreeText: Blood group O positive; comorbid IgA-kappa multiple myeloma and osteonecrosis of the jaw. Preoperative baseline (1st / 2nd sample): aPTT 34.6 s / 34.1 s (normal 21.7–33.9 s), Actin FS prolonged (corrected on mixing), FVIII:C 43.6% / 48.5%, vWF:Ag 19% / 20%, vWF:RCo 11% / 13%, vWF:RCo/vWF:Ag 0.58 / 0.65, FVIII/vWF:Ag 2.29 / 2.43, vWF:CB (I & III) 39% with preserved vWF:CB/vWF:Ag ratio 2.05, fibrinogen 434 / 445 mg/dL. Insufficient response to DDAVP challenge. At 8 months post-op: FVIII normalized (67.1%) while vWF:Ag (29%), vWF:RCo (17.7%), vWF:RCo/vWF:Ag (0.61) remained low, and FVIII/vWF:Ag remained elevated (2.31).
CaseNOTHPOs: HP:0001892, HP:0001873, HP:0030132
(Abnormal bleeding, Thrombocytopenia, Absence of large von Willebrand factor multimers)
CaseNOTHPOFreeText: No personal or perioperative bleeding history (prophylactic rvWF and tranexamic acid given); platelets 233x10^9/L, PT 103.6%, INR 0.98, TT 18.0 s, normal VWF multimer triple structure, low-dose RIPA (0.3 mg/mL) <10%, negative FVIII and vWF:Ag inhibitors (Bethesda method)
CasePreviousTesting: NA
GenotypingMethod: Molecular analysis (PCR) of exon 28 of the VWF gene
Gene: VWF
Variant: Heterozygous mutation p.R1315C/c.3943C>T in exon 28 of the vWF gene (A1 domain)
HGVS: NM_000552.5:c.3943C>T (p.Arg1315Cys)
ClinVarID: 100310
CAID: NA
gnomAD: Maximum allele frequency of 8.476e-7 (1/1179850 alleles, 0 homozygotes) in the European (non-Finnish) population. https://gnomad.broadinstitute.org/variant/12-6019475-G-A?dataset=gnomad_r4